Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles H Nightingale

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Journal of the American Geriatrics Society|January 22, 2003
Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facilityBlair Capitano, O Alice Leshem, Charles H Nightingale, et al.
The Journal of Infection|October 19, 2005
Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectivenessSrividya Kotapati, Joseph L Kuti, Charles H Nightingale, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 28, 2003
Economic benefit of a meropenem dosage strategy based on pharmacodynamic conceptsJoseph L Kuti, Dana Maglio, Charles H Nightingale, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 21, 2004
Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic conceptsSrividya Kotapati, David P Nicolau, Charles H Nightingale, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 4, 2004
Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatographyChonghua Li, Christina A Sutherland, Charles H Nightingale, et al.
Diagnostic Microbiology and Infectious Disease|October 12, 2002
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysisJoseph L Kuti, Charles H Nightingale, Richard Quintiliani, et al.
Connecticut Medicine|June 14, 2003
Role of pharmacodynamics in designing dosage regimens for beta-lactamsSrividya Kotapati, Joseph L Kuti, Charles H Nightingale, et al.
Pharmacotherapy|July 12, 2005
Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenemJoseph L Kuti, Sheryl Horowitz, Charles H Nightingale, et al.
Connecticut Medicine|February 21, 2002
Extended-spectrum beta-lactamases (ESBL)Prachi K Dandekar, Richard Quintiliani, Charles H Nightingale, et al.
Journal of Clinical Pharmacology|September 22, 2006
Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patientsChonghua Li, Joseph L Kuti, Charles H Nightingale, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Journal of the American Geriatrics Society|January 22, 2003
Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facilityBlair Capitano, O Alice Leshem, Charles H Nightingale, et al.
The Journal of Infection|October 19, 2005
Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectivenessSrividya Kotapati, Joseph L Kuti, Charles H Nightingale, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|March 28, 2003
Economic benefit of a meropenem dosage strategy based on pharmacodynamic conceptsJoseph L Kuti, Dana Maglio, Charles H Nightingale, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|July 21, 2004
Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic conceptsSrividya Kotapati, David P Nicolau, Charles H Nightingale, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|November 4, 2004
Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatographyChonghua Li, Christina A Sutherland, Charles H Nightingale, et al.
Diagnostic Microbiology and Infectious Disease|October 12, 2002
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysisJoseph L Kuti, Charles H Nightingale, Richard Quintiliani, et al.
Connecticut Medicine|June 14, 2003
Role of pharmacodynamics in designing dosage regimens for beta-lactamsSrividya Kotapati, Joseph L Kuti, Charles H Nightingale, et al.
Pharmacotherapy|July 12, 2005
Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenemJoseph L Kuti, Sheryl Horowitz, Charles H Nightingale, et al.
Connecticut Medicine|February 21, 2002
Extended-spectrum beta-lactamases (ESBL)Prachi K Dandekar, Richard Quintiliani, Charles H Nightingale, et al.
Journal of Clinical Pharmacology|September 22, 2006
Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patientsChonghua Li, Joseph L Kuti, Charles H Nightingale, et al.
Pageof 7